SCHEMBL24424312

SCHEMBL24424312

COc1cc(-c2cc(C(=O)N3CCC(C(=O)NCc4ncccc4C(F)(F)F)CC3)n[nH]2)c(Cl)cn1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MALT1 Q9UDY8 1/20 0.41
▸ SMO Q99835 3/20 0.41
▸ RBP4 P02753 3/20 0.39
▸ EPHX2 P34913 7/20 0.39
▸ ALDH1A1 P00352 1/20 0.37
▸ PRKAB2 O43741 1/20 0.37
▸ PRKAG1 P54619 1/20 0.37
▸ PRKAA2 P54646 1/20 0.37
▸ PRKAA1 Q13131 1/20 0.37
▸ PRKAG3 Q9UGI9 1/20 0.37
▸ PRKAG2 Q9UGJ0 1/20 0.37
▸ PRKAB1 Q9Y478 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24423557 0.92 SMO (0.44) MALT1SMOALDH1A1POLB
SCHEMBL24424602 0.91 SMO (0.42) MALT1SMOEPHX2ALDH1A1POLB
SCHEMBL30630709 0.90 EPHX2 (0.47) SMOEPHX2CYP2C9
SCHEMBL29243659 0.90 EPHX2 (0.47) SMOEPHX2CYP2C9
SCHEMBL29243462 0.87 SMO (0.42) MALT1SMOEPHX2ALDH1A1POLB
SCHEMBL29585281 0.87 SMO (0.42) MALT1SMOEPHX2ALDH1A1POLB
SCHEMBL24424642 0.86 PRKAA2 (0.39) SMOEPHX2ALDH1A1PRKAB2PRKAG1
SCHEMBL24424319 0.85 CDK9 (0.39) SMOEPHX2PRKAB2PRKAG1PRKAA2
SCHEMBL24423044 0.85 PRKAB2 (0.36) SMOEPHX2ALDH1A1PRKAB2PRKAG1
SCHEMBL24423623 0.85 PRKAA2 (0.40) SMOEPHX2ALDH1A1PRKAB2PRKAG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 — — EP claimed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 — — CN claimed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO claimed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 — — EP disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 — — CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 — — US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD MALT1 3383/4885SMO 1469/4885RBP4 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback